Clinical Trial Update: Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma [Phase 3]

View source ↗

Summary

A Phase 3 trial compares icotinib to placebo as adjuvant therapy in EGFR-mutant lung adenocarcinoma; the trial status is currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• icotinib (icotinib)

Snippet

Sponsor: Betta Pharmaceuticals Co., Ltd. | Conditions: EGFR Positive Non-small Cell Lung Cancer, Adenocarcinoma | Phase 3 | Status: UNKNOWN